EP4 antagonists
US11434246B2 · kind B2 · utility
0Cited by
25References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 5, 2021 |
| Grant date | Sep 6, 2022 |
| Priority date | — |
| Expiry date | Jan 5, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.